Aspire Biopharma Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASBP research report →
Price Chart
About the company
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management.
- CEO
- Kraig T. Higginson
- IPO
- 2025
- Employees
- 2
- HQ
- Estero, FL, US
Get TickerSpark's AI analysis on ASBP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.01M
- P/E
- -1.09
- PEG
- -0.01
- P/S
- 10.35
- P/B
- 0.77
- EV/EBITDA
- -3.39
- Div Yield
- 0.00%
- Gross Margin
- 18.35%
- Op Margin
- -7259.92%
- Net Margin
- -11314.24%
- ROE
- 1993.26%
- ROIC
- -59.81%
Latest fiscal year · YoY change
- Revenue
- $6.20K+0.0%
- Gross Profit
- $-116+0.0%
- Op Income
- $-19,351,291
- Net Income
- $-24,480,848-1768.9%
- EPS
- $-16.38+52.1%
- OCF Growth
- -1756.6%
- FCF Growth
- -1756.6%
- 52W High
- $562.80
- 52W Low
- $0.11
- 50D MA
- $8.09
- 200D MA
- $4.41
- Beta
- 0.15
- RSI (14)
- 54
- Avg Volume
- 38.03K
No earnings-call transcripts are available for ASBP yet.
- Free Float
- 67.4%
- Shares Outstanding
- 115.37K
- Float Shares
- 77.73K
of shares held by institutions
30 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 428.55K | 0 |
| Antara Capital LP | 202.90K | 0 |
| Cibc Private Wealth Group, LLC | 49.13K | 0 |
Held by 7 ETFs
Biggest fund positions in ASBP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 5, 25 | Fell Donald G. | buy | 10,500 |
| Jun 4, 25 | Fell Donald G. | buy | 9,500 |
| Jun 5, 25 | Fell Donald G. | buy | 10,500 |
| Jun 4, 25 | Fell Donald G. | buy | 9,500 |
| Aug 18, 23 | AJJARAPU SURENDRA K | other | 0 |
| Aug 18, 23 | AJJARAPU SURENDRA K | other | 6,834,333 |
| Aug 18, 23 | Doshi Mayur Mansukhlal | other | 0 |
| Aug 18, 23 | Wadhwani Avinash R | other | 0 |
| Aug 18, 23 | PETERSON MICHAEL L | other | 0 |
| Aug 18, 23 | Fell Donald G. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ASBP coverage
Recent articles, reports, and earnings notes.
No research on ASBP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ASBP report →Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program
accessnewswire.com · Sep 9
Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc.
accessnewswire.com · Sep 8
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th
accessnewswire.com · Aug 13
Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue
accessnewswire.com · Aug 10
Aspire Biopharma (NASDAQ:ASBP) Trading Up 10.9% – Time to Buy?
defenseworld.net · Aug 4
Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMB(TM)
accessnewswire.com · Jul 20
Aspire Biopharma's BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs
accessnewswire.com · Jun 24
Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th
globenewswire.com · Jun 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.